Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

Lisa Deschamps Biography and Net Worth

Director of Verona Pharma

Ms Deschamps is CEO and executive board member of a private gene therapy company. Until October 2021, she was Senior Vice President, Chief Business Officer, of Novartis Gene Therapies (GTx), and previously was Head of Novartis’ Global Neuroscience Franchise. During her 25-year career at Novartis, Ms Deschamps gained significant global and US experience in bringing respiratory and other specialized therapeutic area products from the clinic to commercialization. Ms Deschamps has an MBA in General Management from NYU Stern School of Business and a BBA in marketing from IONA College, Hagan School of Business. Ms Deschamps also serves as a non-executive director and strategic advisory board member of Reset Pharmaceuticals.

How do I contact Lisa Deschamps?: The corporate mailing address for Ms. Deschamps and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Lisa Deschamps' contact information.
Has Lisa Deschamps been buying or selling shares of Verona Pharma?: Lisa Deschamps has not been actively trading shares of Verona Pharma within the last three months. Most recently, Lisa Deschamps sold 11,664 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $0.78, for a transaction totalling $9,097.92. Learn More on Lisa Deschamps' trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 1 times. They purchased a total of 39,360 shares worth more than $188,928.00. In the last year, insiders at the sold shares 13 times. They sold a total of 1,178,192 shares worth more than $5,075,998.08. The most recent insider tranaction occured on November, 11th when CEO David Zaccardelli sold 2,400 shares worth more than $12,000.00. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/11/2024.

Lisa Deschamps Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/1/2022	Sell	11,664	$0.78	$9,097.92
11/2/2021	Sell	11,672	$0.66	$7,703.52

Lisa Deschamps Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $38.85

$37.61

$39.33

50 Day Range

MA: $33.12

$27.64

$39.87

2 Week Range

Now: $38.85

$11.39

$40.13

Volume

1,155,655 shs

Average Volume

1,099,138 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Tesla Execs are Freaking Out

From Angel Publishing | Ad

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.